查詢結果分析
來源資料
相關文獻
- Adult Hematopoietic Stem Cell Transplantation in Eastern Taiwan: Initial Results at Tzu Chi Hospital from 2002 to 2005
- 臺東臺灣獼猴自然保護區之植群生態研究
- 顏滄波與東臺灣
- 用GPS檢測東臺灣北回歸線地標
- 池上平原文化景觀的空間過程--土地、社群與國家的論述
- 「白頭待映天山雪,青眼留看地史疑」:畢慶昌(1911∼2001)
- 臺東臺灣獼猴自然保護區蝶類相及其多樣性研究
- 東部國中生的原住民教育優惠政策立場--比較原漢接觸效應
- 臺灣東部原住民的原漢位階意識
- 戰時經濟體制下臺灣東部水產業的統制整合--東臺灣水產會社的成立
頁籤選單縮合
題 名 | Adult Hematopoietic Stem Cell Transplantation in Eastern Taiwan: Initial Results at Tzu Chi Hospital from 2002 to 2005=東臺灣成人血液幹細胞移植之經驗 |
---|---|
作 者 | 朱崧肇; 李啟誠; 王佐輔; 姚朝元; 高瑞和; | 書刊名 | 慈濟醫學 |
卷 期 | 18:2 民95.04 |
頁 次 | 頁97-100+161 |
分類號 | 416.175 |
關鍵詞 | 血液幹細胞移植; 東臺灣; 移植體對抗宿主疾病; 移植存活率; Hematopoietic stem cell transplantation; Eastern Taiwan; Graft versus host disease; Survival; |
語 文 | 英文(English) |
中文摘要 | 目的:血液幹細胞移植(HSCT)能提供許多機會來治癒各種血液學疾病。本院從2002年開始,成為目前東臺灣唯一能執行HSCT的醫學中心,在此提出成人HSCT目前移植成績。病人與方法:自2002年7月至2005年3月間,以13名成人於本院接受HSCT。其中包括5名急性骨髓性白血病、2名急性淋巴性白血病、2名慢性骨髓性白血病、2名再生不良貧血症及2名惡性淋巴瘤。針對這些病人的臨床資料及移植後之存活率及生活品質做作分析統計。結果:13名病人中,9人接受HLA符合之親屬移植,2人接受HLA符合之非親屬移植,2人接受自體幹細胞移植。利用白血球生長激素從周邊血收取的CD34+幹細胞數為6.5 × □/kg,高於從骨髓收取的CD34+幹細胞數1.9 × □/kg。整體幹細胞植入(engraftment)成功率為100%,白血球及血小板植入所需日數之中位數分別為11.4天及11.2天。一年整體無病存活率為90%,預估兩年整體無病存活率為82.5%。第Ⅱ~Ⅳ級急性移植體對抗宿主疾病(acute GVHD)之發生率為72.7%,第Ⅲ~Ⅳ級acute GVHD之發生率為18.2%;慢性移植體對抗宿主疾病(chronic GVHD)之發生率為60%,其中為extensive chronic GVHD者之發生率為30%。11位現在存活者的無病存活天數之中位數為649天。整體存活者的Karnofsky Performance Score之中位數為90分。結論:依目前本院在成人HSCT之初步移植成績,顯示可以提供東臺灣需移植之病人具水準的整體無病存活及移植後正常之生活功能。 |
英文摘要 | Objective: Hematopoietic stem cell transplantation (HSCT) has proved to be an important curative therapy for various hematological disorders. Here we present the first report of adult HSCT at one institution in eastern Taiwan. Patients and Methods: Thirteen patients, 7 men and 6 women, underwent HSCT between July 2002 and March 2005. Their median age was 34 years (range: 22-51). Five patients had acute myeloid leukemia, 2 had acute lymphoblastic leukemia, 2 had chronic myeloid leukemia, 2 had severe aplastic anemia, one had non-Hodgkin's lymphoma and one had Hodgkin's disease. Eleven patients received HLA-identical allogeneic transplantations, including two unrelated donor transplantations. Two patients received autologous transplantations. The conditioning regimens were total body irradiation plus busulfan or busulfan plus cyclophophamide for allogeneic transplantation, and BEAM for autotransplantation. The prevention of graft versus host disease (GVHD) employed standard cyclosporine and methotrexate. Results: The median numbers of CD34 positive cells obtained were 1.9 × 106/kg of patient body weight from bone marrow harvest and 6.5 × 106/kg from peripheral blood stem cell collection. The overall engraftment rate was 100%. The median times to neutrophil and platelet engraftments were 11.4 and 11.2 days, respectively. The one-year event-free and one-year overall survivals were both 90%. Acute GVHD of grade II-IV was seen in 8 out of 11 patients (72.7%) of whom 2 had grade III-IV disease (18.2%). Chronic GVHD developed in 6 out of 10 evaluable patients (60%) with 3 in limited stages and 3 in extensive stages. Eleven patients were alive and free of disease at 124 to 1117 days, with a median survival of 649 days after transplantation. One patient who underwent unrelated transplantation died of CMV pneumonitis on day 67. One patient died of disease relapse on day 485. The median Karnofsky Performance Score of surviving patients was 90%. Conclusion: The study demonstrates that HSCT in our hospital has achieved promising results and patients can obtain long-term disease-free survival and good social function. |
本系統中英文摘要資訊取自各篇刊載內容。